E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01401530
Recruitment Status : Completed
First Posted : July 25, 2011
Last Update Posted : February 8, 2016
Information provided by (Responsible Party):
Eisai Inc. ( Eisai Co., Ltd. )

Brief Summary:
The purpose of this Phase 1 study is to determine the maximum tolerated dose (MTD) through observation of dose limiting toxicity (DLT), which is in advance defined, in patients with peripheral or cutaneous T-cell lymphoma.

Condition or disease Intervention/treatment Phase
Peripheral T-Cell Lymphoma Biological: denileukin diftitox (E7777) Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 13 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase1/1b Clinical Trial of E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma
Study Start Date : July 2011
Actual Primary Completion Date : August 2015
Actual Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: E7777 Biological: denileukin diftitox (E7777)
E7777 will be administered by intravenous (IV) infusion for 5 days from Day 1 through 5 of each cycle (21 days/cycle) with 8 cycles in maximum for E7777 alone therapy. E7777 dose will be escalated from 6 micro-g/kg/day to 12, 15 and then to 18 in a stepwise fashion.

Primary Outcome Measures :
  1. Maximum Tolerated Dose (MTD) [ Time Frame: 3 Weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   20 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

lnclusion Criteria:

  • Male and female patients 20 to less than 80 years of age at the time of informed consent
  • Patients histologically or cytologically diagnosed to have peripheral T -cell lymphoma
  • Patients with a history of chemotherapy (including PUVA and retinoid) that resulted in relapse, recurrence and treatment resistance (just for the administration of E7777 alone)
  • Patients subject to CHOP therapy and without a history of prior treatment with anthracycline or anthraquinone anticancer drugs (just for the administration of E7777 in combination with CHOP therapy)
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
  • No carry-over of beneficial or adverse effects of the prior treatment that may affect the safety evaluation of the investigational drug (excluding Grade 1 neuropathy and alopecia)

Exclusion Criteria:

Brain metastasis with clinical symptoms which requires treatment

Serious systemic infection requiring intensive treatment

Serious complications or histories

History of hypersensitivity to protein therapeutics

Known to be positive for HIV antibody, HCV antibody, or HBs antigen

History of malignancy other than peripheral T-cell lymphoma and less than five years have elapsed since the last remission

Patients who have undergone allogeneic hematopoietic stem cell transplantation

Patients with a relapse within 6 months after autologous hematopoietic stem-cell transplantation

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01401530

Nagoya, Aichi, Japan
Kashiwa, Chiba, Japan
Isehara, Kanagawa, Japan
Chuo-ku, Tokyo, Japan
Sponsors and Collaborators
Eisai Co., Ltd.
Study Director: Tadashi Nakanishi Eisai Co., Ltd.

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Eisai Co., Ltd. Identifier: NCT01401530     History of Changes
Other Study ID Numbers: E7777-J081-101
First Posted: July 25, 2011    Key Record Dates
Last Update Posted: February 8, 2016
Last Verified: February 2016

Keywords provided by Eisai Inc. ( Eisai Co., Ltd. ):
Neoplasms by Histologic Type
T- Cell
Lymphatic Diseases
Lymphoproliferative Disorders
lmmune System Diseases
lmmunoproliferative Disorders

Additional relevant MeSH terms:
Lymphoma, T-Cell
Lymphoma, T-Cell, Peripheral
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Denileukin diftitox
Antineoplastic Agents